EODData

MEMBERSHIP REGISTER LOG IN

FRA, 328: MEIRAGTX HLDGSDL-0000388

01 Apr 2026
LAST:

7.400

CHANGE:
 0.20		OPEN:
7.400		HIGH:
7.400		ASK:
0.000		VOLUME:
0
CHG(%):
2.78		PREV:
7.200		LOW:
7.400		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
01 Apr 267.4007.4007.4007.4000
31 Mar 267.0007.2007.0007.2000
30 Mar 266.5506.6006.3506.6000
27 Mar 266.4506.4506.4506.4500
26 Mar 266.4506.8506.4506.850178
25 Mar 266.3006.3006.3006.3005
24 Mar 266.5006.5006.5006.5005
23 Mar 266.1006.1006.1006.1005
20 Mar 266.2006.2006.2006.2005
19 Mar 266.4006.4006.4006.4000

PROFILE

Name:MEIRAGTX HLDGSDL-0000388
About:MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:450 East 29th Street, New York, NY, United States, 10016
Website:https://meiragtx.com
ISIN:KYG596651029
LEI:54930007YV6NYIOGFZ57

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.30 
Forward P/E:-3.61 
PEG Ratio:-0.26 
Price to Sales:21.91 
Price to Book:-13.97 
Profit Margin:0.29 
Operating Margin:-112.32 
Return on Assets:-0.42 
Return on Equity:-6.11 
Revenue:23.29M 
Shares:80.45M 
Market Cap:595.31M 

TECHNICAL INDICATORS

MA5:6.907.2%
MA10:6.6012.1%
MA20:6.4714.4%
MA50:6.4015.6%
MA100:6.6511.3%
MA200:6.5512.9%
STO9:100.00 
STO14:100.00 
RSI14:63.64 
MTM14:0.85
ROC14:0.13 
ATR:0.24 
Week High:7.400.0%
Week Low:6.3017.5%
Month High:7.400.0%
Month Low:5.8512.9%
Year High:7.906.8%
Year Low:4.0682.4%
Volatility:4.60